Career Enhancement Program

职业提升计划(CEP)的主要目标是吸引和培训优秀人才 希望之城和阿拉巴马大学伯明翰分校的调查人员在进行杰出的 淋巴瘤转化性研究。无论是初级还是成熟的研究人员，他们都希望专注于 或重新聚焦于淋巴瘤可能参与其中。每年支持两个人，最多 两年了。招募希望从事淋巴瘤研究的研究人员可能会 也会发生。孢子每年的直接费用预算为50,000美元，每年还会有额外的费用 希望之城和联合大学的捐款分别为100,000美元和25,000美元。调查人员 可以将资金用于受保护的研究时间、人员和用品的工资支持，以及 会议和培训费用。斯蒂芬·福尔曼博士、亚历山德拉·莱文博士和斯米塔·巴蒂亚博士， 共同代表丰富的指导经验，领导CEP。他们将执导 挑选学员，提供建议和反馈，以及协调年度 复习一下。计划公告通过各种媒体广泛传播，以确保 意识。将作出持续、协调一致的努力，吸引妇女和少数群体 候选人。申请者的审查是基于他们的资格，科学价值和 他们提议的项目的可行性，以及与对方进行有意义的互动的潜力 孢子内的项目和核心。受训人员将从资深教员或 孢子成员；职业促进委员会必须批准该选择，并 可用于协助配对过程。学员提交两次书面进度报告 每年，详细介绍到目前为止的相关工作以及源于 他们的研究。获奖者在一年一度的孢子静修会上展示他们的研究成果。外在的 咨询委员会评估进展情况，并在必要时寻求解决关切问题的办法。 之前的CEP获得者都取得了巨大的成效。王秀丽博士进行了高度的 双特异性重定向嵌合抗原受体(CAR)T细胞的研究前景 对于巨细胞病毒和CD19；这项调查已在 当前孢子。伊丽莎白·布德博士进行的研究导致了CAR T细胞试验的指导 在急性髓系白血病中对抗CD123，她现在是 孢子。亚历克斯·赫雷拉博士，现在是项目3的基本孢子领导者，已经取得了重要的成就 对接受细胞治疗的患者的生物标志物和结果的研究进展；两个主要 翻译研究项目正在进行中。我们预计新一批调查员将 延续进行尖端、变革性淋巴瘤研究的传统。

The primary aim of the Career Enhancement Program (CEP) is to attract and train exceptional investigators at City of Hope and University of Alabama Birmingham in conducting outstanding lymphoma translational research. Both junior and established researchers who desire to focus or refocus on lymphoma may participate. Two individuals are supported every year, for up to two years. Recruitment of investigators who wish to pursue a career in lymphoma research may also take place. SPORE has budgeted direct costs of $50,000 per year, with additional yearly contributions from City of Hope and UAB of $100,000 and $25,000, respectively. Investigators can use funds for salary support for protected research time, personnel and supplies, and meeting and training expenses. Drs. Stephen Forman, Alexandra Levine, and Smita Bhatia, collectively representing extensive mentoring experience, lead the CEP. They will direct the process of selecting trainees, providing advice and feedback, and coordinating an annual review. Program announcements are widely disseminated through various media to ensure awareness. A sustained, concerted effort will be made to attract women and minority candidates. Applicants are reviewed on the basis of their qualifications, the scientific merit and feasibility of their proposed project, and the potential for meaningful interaction with the other projects and cores within the SPORE. Trainees are to select mentors among senior faculty or SPORE members; the Career Enhancement Committee must approve the choice and is available for assisting the matching process. Trainees submit a written progress report twice annually, detailing relevant work to date and manuscripts and presentations that arose from their research. Awardees present their research at the annual SPORE retreat. The External Advisory Board evaluates progress and seeks solutions to points of concern if necessary. Previous CEP recipients have been greatly productive. Dr. Xiuli Wang conducted highly promising research on chimeric antigen receptor (CAR) T cells redirected with dual specificity for cytomegalovirus and CD19; this investigation has been promoted to a full project within the current SPORE. Dr. Elizabeth Budde performed studies that led to a CAR T cell trial directed against CD123 in acute myeloid leukemia, and she is now the clinical lead in Project 4 of the SPORE. Dr. Alex Herrera, now a basic SPORE leader in Project 3, has made significant progress studying biomarkers and outcome in patients who undergo cellular therapies; two main translational research projects are ongoing. We anticipate that the new class of investigators will continue the tradition of performing cutting-edge, transformative lymphoma research.